Publication not explained

This publication has not yet been explained in plain language by the author(s). However, you can still read the publication.

If you are one of the authors, claim this publication so you can create a plain language summary to help more people find, understand and use it.

Featured Image

Read the Original

This page is a summary of: Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk, The Lancet Regional Health - Europe, March 2024, Elsevier,
DOI: 10.1016/j.lanepe.2024.100847.
You can read the full text:

Read

Contributors

The following have contributed to this page